Concurrent administration of donepezil HCl and cimetidine: Assessment of pharmacokinetic changes following single and multiple doses

British Journal of Clinical Pharmacology, Supplement

Volumn 46, Issue 1, 1998, Pages 25-29

  Tiseo, P J ^a   Perdomo, C A ^a   Friedhoff, L T ^a  

^a EISAI INC   (United States)

Author keywords

Acetylcholinesterase inhibitor; Cimetidine; Donepezil; Drug drug interaction

Indexed keywords

CHOLINESTERASE INHIBITOR; CIMETIDINE; DONEPEZIL; HISTAMINE H2 RECEPTOR ANTAGONIST; BRONCHODILATING AGENT; THEOPHYLLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; AGITATION; ELECTROCARDIOGRAPHY; HEADACHE; HEART PALPITATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSOMNIA; NAUSEA; PRURITUS; ULTRAVIOLET SPECTROSCOPY; VERTIGO;

EID: 0032420196     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.0460s1025.x     Document Type: Article

References (20)

1. Whitehouse PJ, Price DL, Clarke AW, Coyle JT, DeLong MR. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-126.
2. Giacobini E. Pharmacotherapy of Alzheimer's disease: new drugs and novel strategies. Prog Brain Res 1993; 98: 447-454.
3. Becker RE. Therapy of the cognitive deficit in Alzheimer's disease: the cholinergic system. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 1-30.
4. Cardozo MG, Iimura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ. QSAR analysis of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem 1992; 35: 584-589.
5. Cardozo MG, Kawai T, Iimura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ. Conformational analysis and molecular shape comparisons of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem 1992; 35: 590-601.
6. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds. Biorg Med Chem Lett 1992; 2: 871-876.
7. Pang YP, Kozikowski AP. Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl] methyl] piperidine in acetylcholinesterase by docking studies with the SYSDOC program. J Comput Aided Mol Design 1994; 8: 683-693.
8. Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y, Yamatsu K. Inhibitory action of donepezil, a novel acetylcholinesterase inhibitor, on cholinesterase. Comparison with other inhibitors. In Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, Volume 2, eds Nagatsu T, Fisher A, Yoshida M. New York: Plenum Press, 1990: 409-413.
9. Nochi S, Asakawa N, Sato T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). Biol Pharm 1995; 18: 1145-1147.
10. Rogers SL, Yamanishi Y, Yamatsu K. E2020 - the pharmacology of a piperidine cholinesterase inhibitor. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 314-320.
11. Rogers SL, Cooper NM, Sukovaty R, Pederson JE, Lee JN, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998; 46 (Suppl. 1): 7-12.
12. Sherman K. Pharmacodynamics of oral E2020 and tacrine in humans: novel approaches. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 321-328.
13. Rogers SL, Friedhoff LT, the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
14. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
15. Rogers SL, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158: 1021-1031.
16. Mihara M, Ohnishi A, Tomono Y et al. Pharmacokinetics of E2020 - a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993; 31: 223-229.
17. Ohnishi A, Mihara M, Kamakura H et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol 1993; 33: 1086-1091.
18. Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP. Differential inhibition of individual human liver cytochrome P-450 by cimetidine. Gastroenterology 1991; 101: 1680-1691.
19. Forgue ST, Reece PA, Sedman AJ, de Vries TM. Inhibition of tacrine oral clearance by cimetidine. Clin Pharmacol Ther 1996; 59: 444-449.
20. Lee JW, Rogers SL, Friedhoff LT, Stiles MR, Cooper NM. Validation and application of an HPLC method for the determination of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl (E2020) in human plasma. Pharm Res 1992; 9: S350.